GeneDx Holdings Corp.
WGS
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $2.6B
$85.99
▼ -1.60%
P/E
-23.75
Mkt Cap
$2.6B
52-Wk Range
$32.21–$170.87
52-Week Range
$32.21 - $170.87
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 32.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AI/ML algorithms analyzing integrated genomic and clinical data
- Founder expertise: Eric Schadt is a pioneering figure in systems genetics and precision medicine
- Centrellis platform creates defensible data moat with longitudinal patient insights
- Patient-centric approach differentiates from competitor-focused models
Bear Case
2 risks
- Above-average volatility (beta 2.0).
- Extreme premium - high expectations embedded
Growth
Turning profitable
Expanding adoption of precision medicine and genomic testing in clinical practice
Value
Extreme premium - high expectations embedded
Momentum
Hot
+55.3% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying WGS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 27, 2026
AUG 3, 2026
Reported EPS of $0.01 vs -$0.19 consensus (+105.3% surprise). Revenue of $114.4M vs $111.0M expected (+3.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+105.3%
Revenue trend · last 8Q
—
+67%
+40%
+46%
+52%
+27%
+17%
+11%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$76.9M
$95.6M
$87.1M
$102.7M
$116.7M
$121.0M
$102.3M
$114.4M
Margins · last 8Q
Gross
68.4%
Operating
-15.3%
Profit
-15.5%
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$74.00
▼ -13.9% vs $85.99
Latest: TD Cowen · Jul 15, 2026
1 analyst covering
vs Industry
How WGS stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related